DIADIA0.35%
SPYSPY0.54%
QQQQQQ1.33%
Trending
Top trending tickerXRPXRP4.00%
ETHETH4.00%
MPMP2.41%
RTXRTX0.11%
NVDANVDA1.18%
CADLCADL0.21%
IRENIREN4.35%
VELOVELO4.21%
UAMYUAMY2.37%
AMDAMD4.42%
Top trending tickerXRPXRP4.00%
ETHETH4.00%
MPMP2.41%
RTXRTX0.11%
NVDANVDA1.18%
CADLCADL0.21%
IRENIREN4.35%
VELOVELO4.21%
UAMYUAMY2.37%
AMDAMD4.42%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolCMPXnews
Exchange: NASDAQ·Updated 04:57 AM EDT
CMPX logo

CMPXCompass Therapeutics Inc

$2.04
$0.0195
(0.96%)
Pre-Market
Prev Close $2.02
EarningsAug 14
Mkt Cap$369.18M
Vol1,307.00
News
all
press releases
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...
PR Newswire
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
News Placeholder
Canaccord Genuity Group Lowers Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00
Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday...
MarketBeat
News Placeholder
Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX)
Citizens Jmp restated a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday...
MarketBeat
News Placeholder
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low - What's Next?
Compass Therapeutics (NASDAQ:CMPX) Reaches New 52-Week Low - Here's Why...
MarketBeat
News Placeholder
Compass Therapeutics Touts Stunning PFS Win in COMPANION-002 as Crossover Muddy OS Data
Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called absolutely stunning progression-free survival results from the company's phase II/III...
MarketBeat
News Placeholder
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.read more...
Benzinga
News Placeholder
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Monday...
MarketBeat
News Placeholder
This Small-Cap Biotech Is Gearing Up For A Make-Or-Break Cancer Drug Data Drop
The biotech firm is set to report topline data on secondary endpoints from its Phase 2/3 trial for advanced biliary tract cancer on Monday.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.